- Home
- SNCY vs CSTL Comparison
SNCY vs CSTL Comparison
Compare SNCY & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- CSTL
- Stock Information
- Founded
- SNCY 1982
- CSTL 2007
- Country
- SNCY United States
- CSTL United States
- Employees
- SNCY N/A
- CSTL N/A
- Industry
- SNCY Air Freight/Delivery Services
- CSTL Medical Specialities
- Sector
- SNCY Consumer Discretionary
- CSTL Health Care
- Exchange
- SNCY Nasdaq
- CSTL Nasdaq
- Market Cap
- SNCY 634.5M
- CSTL 697.9M
- IPO Year
- SNCY 2021
- CSTL 2019
- Fundamental
- Price
- SNCY $11.31
- CSTL $23.68
- Analyst Decision
- SNCY Buy
- CSTL Strong Buy
- Analyst Count
- SNCY 6
- CSTL 6
- Target Price
- SNCY $18.50
- CSTL $37.67
- AVG Volume (30 Days)
- SNCY 1.1M
- CSTL 337.4K
- Earning Date
- SNCY 10-29-2025
- CSTL 11-03-2025
- Dividend Yield
- SNCY N/A
- CSTL N/A
- EPS Growth
- SNCY 20.75
- CSTL N/A
- EPS
- SNCY 1.07
- CSTL N/A
- Revenue
- SNCY $1,100,145,000.00
- CSTL $346,269,000.00
- Revenue This Year
- SNCY $5.97
- CSTL N/A
- Revenue Next Year
- SNCY $10.61
- CSTL N/A
- P/E Ratio
- SNCY $10.73
- CSTL N/A
- Revenue Growth
- SNCY 3.76
- CSTL 20.40
- 52 Week Low
- SNCY $8.10
- CSTL $14.59
- 52 Week High
- SNCY $18.59
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- SNCY 40.29
- CSTL 59.04
- Support Level
- SNCY $11.18
- CSTL $22.28
- Resistance Level
- SNCY $12.11
- CSTL $23.71
- Average True Range (ATR)
- SNCY 0.46
- CSTL 0.93
- MACD
- SNCY -0.11
- CSTL -0.02
- Stochastic Oscillator
- SNCY 13.68
- CSTL 76.60
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.